Recent developments in molecular biology have allowed precise quantitative analysis of herpesvirus DNA in many biological fluids. Th is paper reviews the clinical utility of performing quantitative polymerase chain reaction testing for herpesviruses. In particular, the assessment of the cytomegalovirus (CMY) DNA load in blood with regard to the development ofCMY disease in immunocompromised patients is discussed in greater detail. Relevant information exists to support measuring the CMY burden in the blood of AIDS and transplant patients for diagnostic and treatment monitoring purposes, and, to a lesser extent, to envision the monitoring of the circulating Epstein-Barr virus load for the prevention of pose-transplant lymphoproliferative disorders. On the ocher hand, there are controversia l data on the clinical utility of measuring the herpes simplex virus (HSY) load in cerebrospinal fluid of patients with HSY encephalitis and on the relationship between the human herpesvirus 8 DNA load in diverse biological fluids and the presence of Kaposi's sarcoma. There is a paucity of information about the clinical impact of quantifying the other human herpesviruses (varicella-zoster virus, and human herpesviruses 6 and 7).
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PmoNALUSEO Y·DOIJFCOPY M embers of the Herpesviridae family are large DNAcontaining, enveloped viruses (1). Eight of these viruses specifically infect humans. These viruses have been classified into three subfamilies (alpha, beta and gamma) based on host cell tropism and other biological properties (Table 1) . The viral genome ranges from 125 kb (varicellazoster virus [VZV] ) to 229 kb (cytomegalovirus [CMV] ). Herpesvirus genomes contain two unique sequences (long and short) that are flanked by repeated DNA sequences (terminal and internal repeats). These internal regions can be inverted and lead to different isomeric forms. The replication ofherpesviruses is highly regulated, first with the expression of immediate-early genes coding for regulatory proteins, followed by early genes (thymidine kinase, DNA polymerase). After DNA replication, the late structural genes coding for glycoproteins are expressed. One of the basic properties of herpesviruses consists of inducing lifelong latent infections in their natural hosts.
HOW TO MEASURE THE HERPESVIRUS LOAD
Following the development of methods to monitor the human immunodeficiency virus (HIV) load, scientists applied the same principles to the herpesviruses. The four major objectives in measuring the herpesvirus load are the following:
1. to establish or confirm the presence of disease (diagnosis);
2. to evaluate the risk of disease (pre-emptive strategy);
3. to monitor antiviral therapy;
4. indirectly to assess for the emergence of drugresistant strains.
One of the most critical initial steps in measuring the herpesvirus load consists of selecting the right sample for quantification . In other words, it is necessary to know about the active site of viral replication. Whenever possible, readily accessible sites such as blood or urine should be selected once it is suspected that viremia or viruria have occurred. The next step consists of choosing the right methodology (ie, nonmolecular versus molecular methods and detection based on target amplification versus signal amplification). It is important that key methodological variables be assessed, including sensitivity, specificity, predictive values, reproducibility (intraand interassay), lower limit of detection and dynamic range. Finally, after the type of samples and methodology are selected, the next step consists of determining the best viral load threshold or cutoff value associated with viral disease. The latter needs to be evaluated in prospective studies performed in different clinical settings.
There are many ways to evaluate the herpesvirus load; some methods are associated with poor standardization and reproducibility, and other methods have been well evaluated and are commercially available. To date, most quantitative methods have been developed and evaluated for the purpose of measuring the CMV viral load in blood. The characteristics of the nonmolecular and molecular methods for CMV quantifi-34C (2) (3) (4) . Recently, there has been some interest in evaluating the HSV DNA load to assess the prognosis of HSV encephalitis. In a study by Domingues et al (5) , the amounts of HSV DNA in CSF from individuals with HSV encephalitis ranged from less than 25 to 18,000 copies/µ,L in CSF when obtained before or within four days of the initiation of therapy. More significantly, the authors reported a poorer clinical outcome for patients with a high viral DNA load in CSF (greater than 100 copies/µ,L). Such patients were more likely to have a reduced level of consciousness and cerebral lesions detected by a computed tomography scan. The same study also provides preliminary indications that HSV DNA load monitoring over time may help to assess patients' response to acyclovir. Indeed, in five of six individuals with serial CSF evaluations, HSV-1 DNA levels declined during acyclovir therapy. The only patient who had an increased HSV DNA load during therapy died on day 8 (5). In contrast, other investigators failed to demonstrate a clear correlation between the HSV-1 DNA burden in CSF and clinical outcome or radiological findings (6 , 7) . This has led investigators to speculate that indirect (immune-mediated) mechanisms may play a significant role in the development of cerebral pathology in individuals with HSV encephalitis. To date, there has been very limited information about the use of quantitative HSV PCR with swabs obtained from patients with genital lesions or asymptomatic genital shedding. Hobson et al (8) evaluated the HSV DNA content from swabs of genital secretions using quantitativecompetitive PCR. They showed that higher HSV DNA levels were shed when patients had genital lesions.
In summary, more studies need to be performed to resolve the conflicting data about the clinical value of performing quantitative PCR for HSV-1 in CSF during HSV encephalitis. Also , the utility of measuring the HSV-2 DNA burden for the management of genital herpes (ie, to assess antiviral efficacy and risk of transmission) requires further investigation.
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CMVLOAD
Following primary infection or during reactivation in immunocompromised patients, CMV can be shed in numerous body fluids , including urine, saliva , genital secretions and blood. Because CMV viremia is associated closely with CMV disease (9, 10) , there has been considerable interest over the past years in monitoring the blood viral load in different clinical settings. In the HIV-infected population, CMV retinitis used to be a dreadful complication associated with a collapsed immune system (CD4 T cell counts less than sox 10 6 /L); many studies have confirmed the clinical utility of monitoring the circulating viral load to predict CMV retinitis. Bowen et al ( 11) showed that a positive CMV PCR result using whole blood was associated significantly with the development of disease, with a relative hazard of20.15. Moreover, in PCR-positive patients, each 0.25 log 1 o increase in viral load increased the risk of disease by 1.37-fold. Similarly, Spector et al ( 12) demonstrated recently that each log 1 o increase in baseline CMV DNA load in plasma resulted in a 3.1-fold increase in risk of CMV disease and a 2.2-fold increase in mortality. We and other investigators have shown that the mean number of CMV DNA copies in leukocytes of AIDS patients with CMV retinitis was 29-to 39-fold higher than the viral load present in asymptomatic patients with low CD4 T cell counts (less than lOOx 10 6 /L) (13 , 14) .
In a recent study, we sought to evaluate the clinical utility of quantitative versus qualitative PCR and the use of polymorphonuclear leukocytes (PMNLs) versus plasma for the diagnosis of CMV retinitis in HIV-infected patients (15) . When the number of CMV copies in the two types of samples was normalized per 1 mL of whole blood, the CMV DNA burden was consistently higher in the PMNL fraction compared with plasma for both asymptomatic and symptomatic patients. The sensitivity, specificity, and positive and negative predictive values of qualitative PCR using PMNL to detect the presence of CMV disease were 100%, 58%, 38% and 100%. respectively, compared with 70%, 93%, 74% and 92%, respectively, for qualitative PCR-plasma and 93%, 92%, 76% and 98%, respectively, for quantitative PCR-PMNL using a cutoff of 16,000 copies/mL (or about 350 copies/10 5 PMNLs). Thus, the best strategy for Boivin USE diagnosing CMV disease in these individuals relies on the quantitative assessment of the viral DNA load in PMNLs. On the other hand, the use of plasma is more convenient and does not require quantification. However, the last option, although very specific, does not rule out the presence of disease in the case of a negative result (sensitivity of 70%).
More recently, the monitoring of the blood CMV DNA load has been shown to be beneficial for enacting pre-emptive therapy in solid organ transplant (SOT) recipients . In patients with renal transplants , levels of CMV DNA exceeding 1000 copies/ 105 PMNLs in week 4 after transplantation are highly predictive of subsequent occurrence of symptomatic infections ( 16) . In addition, patients with higher initial CMV DNA levels require a longer time to become PCR negative on initiation of ganciclovir therapy. The importance of the blood viral load in the pathogenesis of CMV disease was also demonstrated in liver transplant recipients (17) . It is of interest that Cope et al (17) showed that the blood virus load and the total methylprednisolone dosage were the only independent risk factors for CMV disease in this population as assessed by a multivariate analysis. In the latter study, the donor-recipient CMV serological status was not an independent risk factor because it could be explained by an elevated virus load. Quantitative CMV PCR is also useful in heart allograft recipients where viral DNA levels at least 500 copies/I µ,g of total DNA from whole blood can be used to differentiate symptomatic CMV infections from other infections and rejection, although some overlap in levels may occur ( 18) . We found that the CMV DNA load in leukocytes of bone marrow transplant (BMT) recipients with CMV disease was significantly lower than that in SOT recipients and HIV-infected patients with comparable CMV disease ( 19) . Factors other than the circulating virus load (such as graft-versus-host disease) are probably also important in the pathogenesis ofCMV pneumonitis in this population and must be considered when therapeutic decisions are made. As a result, a low blood viral load threshold probably needs to be selected in pre-emptive protocols after BMT (20) . Nevertheless, a high CMV load in plasma during the first three months after BMT (particularly I 0 4 copies/mL or greater) was recently associated with late development (after day 120) of CMV disease (21) .
Another potential use of quantitative PCR consists of monitoring the CMV burden at the site of disease where active viral replication should take place. Such an approach may be appropriate particularly for some types of CMV disease associated with a lower blood viral load, such as CMV encephalitis/myelitis in AIDS patients and CMV pneumonitis in BMT recipients. In that regard, Shinkai et al (22) reported a higher viral load in AIDS patients with polyradiculopathy compared with those with CMV encephalitis (median 4632 versus 612 copies/µ,L of CSF) . Arribas et al (23) also found a correlation between the viral load in CSF and disease outcome with patients having more than 10 3 copies/8 µ,L of CSF experiencing more severe disease. We also demonstrated the important role of CMV in the pathogenesis of CMV pneumonitis by performing a quantitative analysis of the CMV DNA load in bronchoalveolar lavage (BAL) cells of immunocompromised patients (24) . We found
36(
Y·DO OTCCl'Y more than a 2 log 10 difference in the amounts of CMV DNA in BAL cells between patients with asymptomatic viral shedding and those with definite CMV pneumonia as defined by the presence of typical intranuclear viral inclusions in lung biopsies or BAL cells. Quantitative CMV PCR assays have been used recently to monitor antiviral therapy in patients with established CMV disease. Roberts et al (16) estimated that CMV DNA levels declined exponentially with ganciclovir treatment, with an average half-life of 3.3 days. Our group also reported that a 10-day course of induction therapy with intravenous ganciclovir resulted in a 1.5 to 2.0 log 1 o decrease in the blood CMV DNA load in SOT recipients and AIDS patients (19) . In contrast, the viral load reduction after induction therapy was much smaller (about 1.0 log 10 ) in BMT recipients with CMV disease. Foscarnet therapy for 10 days has also been shown to decrease the levels of CMV DNA by more than l log1 0 (20,328 to 622 copies/1.5 x 10 5 PMNLs) in AIDS patients with asymptomatic CMV viremia (25) . It is of more interest that rising levels of CMV DNA in the blood during antiviral treatment can help predict disease recurrence and the emergence of drug-resistant CMV strains in HIV-infected patients (26) . Our group was the first to report a correlation between increasing CMV DNA levels in PMNL during therapy and the detection of specific CMV UL97 mutations conferring ganciclovir resistance in the same samples (27) . We subsequently reported that plasma could be substituted for PMNL to detect UL97 mutations and predict drug failure (28) . An example of a longitudinal analysis of the CMV viral load in an AIDS patient with CMV retinitis and subsequent emergence of a ganciclovir-resistant strain is shown in Figure 1 .
In summary, several longitudinal, natural history studies have established PCR breakpoints for CMV disease in different clinical settings. However, there is a lack of randomized, controlled studies that validate the concept of using the CMV load in pre-emptive strategies. Many questions, such as the following, remain unanswered. Which is the best type of sample to use for monitoring: PMNLs versus plasma? What is the best interval for CMV monitoring? What is the role of other viral or host factors in the development of CMV disease? In addition, multi-institutional quality control programs are urgently needed to standardize and validate PCR protocols.
EPSTEIN-BARR VIRUS LOAD
Epstein-Barr virus (EBV) is one of the most common and widely disseminated human viruses. It is the causative agent of infectious mononucleosis and has been associated strongly with two malignancies: Burkitt's lymphoma and nasopharyngeal carcinoma. More recently, it has been implicated in the etiology of B cell lymphomas in immunocompromised patients, patients with Hodgkin's disease, oral hairy leukoplakia and post-transplant lymphoproliferative disorders (PTLD). EBV infects B cells and epithelial cells. In general, infection of B lymphocytes is latent, whereas active replication (lytic cycle) can take place in epithelial cells of the oropharynx.
Quantitative EBV PCR has been used mainly in the context of PTLD. This syndrome may vary from infectious mono- 'SI" 'SI"
. 
tis, th e number of clays of antiviral therapy and the viral titre (in p arentheses) are indica ted by arrows . O n November 13, 1996, a blood CM V isolate was fou nd to be resistant to ga nciclovir (50% inhibitory concentration 10.8 µM) due to a U L97 m uta tion at codon "94 (Ala® Val). CCV Canciclovir
nucleosis-like illness to solid localized tumours and is fatal in about 70% of cases (29) . Some investigators have provided evidence for an association between high copy numbers of EBV in the peripheral blood and PTLD . Rowe et al (30) showed that the blood viral burden was significantly higher in paediatric transplant patients with PTLD (4000 copies/10 5 lymphocytes) compared with transplant patients without PTLD (fewer than eight copies) and in healthy seropositive individuals (fewer than 0.1 copies) . Furthermore, in that study, 13 of 14 (92.8%) patients with PTLD had greater than 500 copies/10 5 lymphocytes compared with none of the 12 transplant recipients without PTLD. The importance of the EBV DNA load in that context has been confirmed by other investigators, and viral load thresholds have been adopted at some transplant centres for enacting pre-emptive therapy with ganciclovir and cytogam (31,32). There is also mounting evidence that the presence of cellfree EBV DNA may be a good marker of active viral infection similar to the situation reported for CMV. Indeed, the concentration of EBV DNA in plasma was shown to correlate with the clinical status of patients with infectious mononucleosis (33) . The amounts of EBV DNA in oropharyngeal cells also seem to be higher in primary versus reactivation infection and in patients with PTLD versus those without PTLD (34) .
Although the EBV viral load seems to be an important factor in the pathogenesis of PTLD, several questions remain to be answered before routine EBV monitoring after transplantation can be recommended. These include the following. ls it advisable to monitor both seronegative recipients (the group at highest risk) and seropositive patients? What is the optimal Can J Infect Dis Vol 10 Suppl C May 1999 threshold value for enacting pre-emptive therapy or reducing immunosuppression? Should investigators use a quantitative PCR assay based on leukocytes or a qualitative assay based on plasma for patient monitoring? Another important point concerns the effects of antiherpes agents on the EBV DNA load in blood or oropharyngeal cells . A recent preliminary report indicated no immediate effects of foscarnet on the EBV DNA load in the plasma of HIV-infected patients, although more detailed studies are needed on this aspect (35) .
HUMAN HERPESVIRUS 8 LOAD
Human herpesvirus (HHV)-8, also known as Kaposi's sarcoma (KS) -associated herpesvirus, is a new member of the gamma Herpesvirinae subfamily discovered in 1994 by Chang et al (36) . This virus has been associated with AIDS -and nonAIDS-related KS , multicentric Castleman's disease and body cavity-based lymphomas (37) (38) (39) . Viral DNA has been detected in numerous body fluids , including blood (especially B lymphocytes) , semen and saliva. Specific HHV-8 DNA sequences have been found in more than 95% of KS lesions from both HIV-positive and HIV-negative persons, in 20% to 71 % of peripheral blood leukocytes (PBL) from HIV-infected patients with KS, and in O to 11 % of PBL from HIV-infected patients without KS (40, 41) .
Recent quantitative PCR studies have provided some insights into the pathogenesis of KS and the relationship between HHV-8 and KS . Using semiquantitative PCR, Mendez et al (42) measured the intratumoral HHV-8 load in 12 patients previously diagnosed with KS by histopathological examination . They found higher levels of HHV-8 DNA in patients with Boivin USEC ~Y-DO cc TABLE 4 Clinical impact of quantitative assays for human herpesviruses (HHV) multicentric and visceral involvement than in patients with localized disease. In addition , in subjects with localized skin disease, the nodular stage was associated with higher levels of HHV-8 DNA than with the patch or plaque stages. Recently, Koelle et al (43) detected HHV-8 DNA sequences in saliva samples from 75% of HIV-seropositive patients with KS. However, in that study, the levels of salivary HHV-8 DNA were not associated with the presence of oral KS lesions. In another study, quantitative PCR for HHV-8 was performed on DNA extracted from blood samples collected from a renal transplant patient diagnosed with KS eight months after transplantation (44) . This report showed that the peak HHV-8 viral load was observed one week after KS developed and that a rapid decrease of the viral burden followed the termination of therapy with immunosuppressive drugs.
We designed a reproducible quantitative-competitive PCR assay for HHV-8 to determine the number of viral copies in PBL samples from a Canadian cohort of HIV-seropositive individuals with low CD4 T cell counts (250x 10 6 /L) with or without KS (45) . We initially showed that HHV-8 DNA sequences were detectable in 12 of 29 (41 %) of PBL from Canadian AIDS patients with KS compared with four of 43 (9.3%) from those without KS (P=0.003). However, the peak HHV-8 DNA load in PCR-positive patients with KS (mean 425 copies/0.2 µ.g of PBL DNA) did not significantly differ from the load found in the PCR-positive patients without KS (mean 218 copies). We then sought to determine whether common anti-CMV drugs (eg, ganciclovir and foscarnet) had any in vivo effects on the circulating HHV-8 DNA burden (45) . Previous in vitro studies had demonstrated relative HHV-8 susceptibility to ganciclovir 38( (50% inhibitory concentration [ICso) value of about 5 µ.M) and foscarnet (ICso value of about 100 µ.M) (46, 47) . The administration of either intravenous ganciclovir or foscarnet in our patients with both CMV disease and KS induced a significant and rapid decrease in the blood CMV DNA load but not in the HHV-8 viral burden. From our results, we hypothesize that most of the HHV-8 genome detected in the blood of AIDS patients with KS is probably from latent, nonreplicative viruses.
In summary, it appears that unlike the situation with CMV, the measure of the circulating HHV-8 DNA load is not a reliable surrogate marker for disease activity (ie, KS) or response to antiviral therapy. However, larger prospective studies are needed to confirm these preliminary observations. Many other important questions concerning the HHV-8 DNA load remain unanswered . For example, are there other acute or chronic forms of HHV-8 infection in which active replication takes place and where quantitative PCR assays can be of interest? Also , can active antiviral drugs be beneficial in blocking viral replication at an early stage and preventing the development of KS in HIV-infected patients?
OTHER HERPESVIRUSES AND CONCLUSIVE REMARKS There are far less data concerning the role of quantitative PCR for the clinical management of other human herpesviruses (VZV and HHV-6 and HHV-7). Consequently, they will not be discussed further in this review. It should be noted , however, that HHV-6 has been recently linked to many posttransplantation disorders , including infectious complications (pneumonitis, encephalitis) and organ rejection/graft-ver-sus-host disease (48, 49) . Quantitative analysis of the HHV-6 DNA load should shed some light on the causative role of this virus in posttransplantation complications.
In conclusion, the relevance of measuring the CMV load and, to some extent, the EBV load, has been well demonstrated for the clinical situations listed in Table 4 . Debate continues on the clinical utility of performing quantitative delermination of the HSV and HHV-8 viral loads. There is a paucity of data at the present time to evaluate the impact of quantifying the VZV, HHV-6 and HHV-7 DNA burdens. It is hoped that more standardized and rapid detection procedures of amplified viral products using realtime PCR (COBAS TaqMan, Roche Molecular Systems, New Jersey), for example, will allow more widespread use of these molecular methods in the future. 
